Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H48O5 |
| Molecular Weight | 512.7205 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@]3(C)[C@]([H])(C(=O)C=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@]5(C)CC[C@@]34C)[C@@]1(C)CC[C@@H](OC(C)=O)[C@]2(C)C(O)=O
InChI
InChIKey=HMMGKOVEOFBCAU-BCDBGHSCSA-N
InChI=1S/C32H48O5/c1-18-9-12-28(4)15-16-30(6)21(25(28)19(18)2)17-22(34)26-29(5)13-11-24(37-20(3)33)32(8,27(35)36)23(29)10-14-31(26,30)7/h17-19,23-26H,9-16H2,1-8H3,(H,35,36)/t18-,19+,23-,24-,25+,26-,28-,29+,30-,31-,32-/m1/s1
Acetyl-11-keto-beta-boswellic acid (AKBA), a pentacyclic triterpene, is a component of gum resin of Boswellia serrata. It inhibits 5-lipoxygenase in a selective, enzyme directed, non-redox, and noncompetitive manner. In addition, AKBA inhibited topoisomerase I. It induces apoptosis and exerts antineoplastic properties. 5-LOXIN, a dietary supplement ingredient (Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid) is effective in reducing pain and improving physical functioning in osteoarthritis patients.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1781 |
|||
| 1.5 µM [IC50] | |||
Target ID: GO:0006915 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | 5-LOXIN Approved Use5-Loxin is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme. In human studies, 5-LOXIN® promotes joint health and function and protects against collagen degradation, an important component of connective tissues. |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
5-LOXIN, a dietary supplement ingredient (Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid): osteoarthritis patients received either 100 mg or 250 mg of 5-Loxin daily or a placebo for 90 days. Significant improvements in pain score and functional ability were recorded in the treatment group supplemented with 250 mg 5-Loxin as early as 7 days after the start of treatment.
Route of Administration:
Oral
Treatment of meningioma cells by Acetyl-11-Keto-β-Boswellic Acid (AKBA) revealed a potent cytotoxic activity with half-maximal inhibitory concentrations in the range of 2-8 microM. At similar, physiologically achievable concentrations, AKBA rapidly (within minutes) and potently inhibited the phosphorylation of extracellular signal-regulated kinase 1 and 2 (Erk-1 and Erk-2) in meningioma cells stimulated with platelet-derived growth factor BB.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
67416-61-9
Created by
admin on Sat Dec 16 05:55:22 GMT 2023 , Edited by admin on Sat Dec 16 05:55:22 GMT 2023
|
PRIMARY | |||
|
DTXSID601303401
Created by
admin on Sat Dec 16 05:55:22 GMT 2023 , Edited by admin on Sat Dec 16 05:55:22 GMT 2023
|
PRIMARY | |||
|
11168203
Created by
admin on Sat Dec 16 05:55:22 GMT 2023 , Edited by admin on Sat Dec 16 05:55:22 GMT 2023
|
PRIMARY | |||
|
1076261
Created by
admin on Sat Dec 16 05:55:22 GMT 2023 , Edited by admin on Sat Dec 16 05:55:22 GMT 2023
|
PRIMARY | |||
|
BS16QT99Q1
Created by
admin on Sat Dec 16 05:55:22 GMT 2023 , Edited by admin on Sat Dec 16 05:55:22 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
